Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$14.1B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$1.34B |
| 3 |
Visa
V
|
+$714M |
| 4 |
VanEck Semiconductor ETF
SMH
|
+$638M |
| 5 |
HONA
Honeywell Aerospace
HONA
|
+$508M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.58B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$1.74B |
| 3 |
Apple
AAPL
|
+$1.66B |
| 4 |
Advanced Micro Devices
AMD
|
+$1.3B |
| 5 |
Amazon
AMZN
|
+$1.23B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 55.34% |
| 2 | Technology | 17.88% |
| 3 | Financials | 5.92% |
| 4 | Consumer Discretionary | 4.3% |
| 5 | Communication Services | 3.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4101
Takeda Pharmaceutical
TAK
$58.5B
| $76.8K | ﹤0.01% |
4,792
+3,551
| +286% | +$58.8K |
|
4102
Cerence
CRNC
$374M
| $76.2K | ﹤0.01% |
6,730
-4,615
| -41% | -$45.2K |
|
4103
i3 Verticals
IIIV
$286M
| $75.9K | ﹤0.01% |
3,553
-3,753
| -51% | -$78.2K |
|
4104
Palisade Bio
PALI
$383M
| $75.8K | ﹤0.01% |
36,253
+34,023
| +1,526% | +$67K |
|
4105
Bel Fuse Inc Class A
BELFA
$2.97B
| $75.7K | ﹤0.01% |
260
-62
| -19% | -$15.1K |
|
4106
Lexeo Therapeutics
LXEO
$391M
| $75.7K | ﹤0.01% |
16,257
+4,092
| +34% | +$22.1K |
|
4107
Pangaea Logistics
PANL
$544M
| $75.5K | ﹤0.01% |
11,622
+1,003
| +9% | +$7.61K |
|
|
CHCT
4108
Community Healthcare Trust
CHCT
$424M
| $75.4K | ﹤0.01% |
4,124
-994
| -19% | -$17.3K |
|
4109
Flotek Industries
FTK
$883M
| $75.4K | ﹤0.01% |
3,204
+451
| +16% | +$8.73K |
|
4110
Innovator US Equity Buffer ETF November
BNOV
$200M
| $75.2K | ﹤0.01% |
+1,573
| New | +$73.3K |
|
4111
Perspective Therapeutics
CATX
$356M
| $75.2K | ﹤0.01% |
22,047
+6,998
| +47% | +$26.4K |
|
4112
Corbus Pharmaceuticals
CRBP
$205M
| $75.1K | ﹤0.01% |
8,002
-12,780
| -61% | -$121K |
|
|
SQMX
4113
FT Vest U.S. Equity Quarterly Max Buffer ETF
SQMX
$54.8M
| $75.1K | ﹤0.01% |
2,194
| – | – |
|
|
TMQ
4114
Trilogy Metals
TMQ
$603M
| $74.8K | ﹤0.01% |
21,317
+13,047
| +158% | +$53.7K |
|
4115
iShares Core MSCI Emerging Markets ETF
IEMG
$165B
| $74.6K | ﹤0.01% |
900
+500
| +125% | +$39.9K |
|
4116
Black Diamond Therapeutics
BDTX
$121M
| $74.1K | ﹤0.01% |
40,057
-27,222
| -40% | -$66.6K |
|
4117
Xperi
XPER
$282M
| $74K | ﹤0.01% |
8,997
-5,635
| -39% | -$40.8K |
|
4118
OneWater Marine
ONEW
$195M
| $73.9K | ﹤0.01% |
6,560
-729
| -10% | -$7.84K |
|
4119
Biote Corp
BTMD
$43.3M
| $73.8K | ﹤0.01% |
39,038
-3,681
| -9% | -$7.58K |
|
4120
Consolidated Water Co
CWCO
$459M
| $73.4K | ﹤0.01% |
2,487
-749
| -23% | -$23.5K |
|
4121
Palladyne AI
PDYN
$285M
| $73.3K | ﹤0.01% |
12,059
+5,911
| +96% | +$39.1K |
|
4122
Lightbridge
LTBR
$267M
| $73.3K | ﹤0.01% |
8,340
+2,470
| +42% | +$27.8K |
|
4123
Core Molding Technologies
CMT
$210M
| $73K | ﹤0.01% |
3,092
-562
| -15% | -$13.8K |
|
4124
Atlanticus Holdings
ATLC
$1.42B
| $72.6K | ﹤0.01% |
710
-2,097
| -75% | -$170K |
|
|
RPC
4125
Ridgepost Capital
RPC
$912M
| $72.4K | ﹤0.01% |
9,202
-1,545
| -14% | -$12.3K |
|
Similar funds
Barclays's Q2 2026 Portfolio in Review
As of Q2 2026, Barclays held 5,723 positions worth $521B, up 25% from $416B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2026 filing shows 722 new, 1,729 increased, 2,511 reduced and 392 closed positions. Its largest new stake was Honeywell Aerospace: 2,302,561 shares worth $509M. The largest sale was NVIDIA, an estimated $4.58B.
By sector, the portfolio is most concentrated in Miscellaneous at 55% of assets, up from 46% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2026 buy was Honeywell Aerospace: 2,302,561 shares worth $509M.
- Barclays added most to iShares MSCI Emerging Markets ETF in Q2 2026, an estimated $14.1B increase.
- Barclays's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $4.58B.
- Barclays fully exited Masimo in Q2 2026, selling an estimated $488M.
- Barclays's ten largest holdings make up 43% of its $521B portfolio in Q2 2026.
- Barclays opened 722 new positions and closed 392 in Q2 2026.
- Barclays's portfolio value rose 25% quarter-over-quarter to $521B.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.